PMID- 37971356
OWN - NLM
STAT- MEDLINE
DCOM- 20240208
LR  - 20240409
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 215
IP  - 2
DP  - 2024 Feb 7
TI  - Immunological dynamic characteristics in acute myeloid leukemia predict the 
      long-term outcomes and graft-versus host-disease occurrences 
      post-transplantation.
PG  - 148-159
LID - 10.1093/cei/uxad123 [doi]
AB  - To investigate the relationship between immune dynamic and 
      graft-versus-host-disease (GVHD) risk, 111 initial diagnostic acute myeloid 
      leukemia patients were reviewed. The flow cytometry data of 12 major lymphocyte 
      subsets in bone marrow (BM) from 60 transplant patients at four different time 
      points were analyzed. Additionally, 90 immune subsets in peripheral blood (PB) of 
      11 post-transplantation on day 100 were reviewed. Our results demonstrated that 
      transplant patients had longer OS compared to non-transplant patients 
      (P < 0.001). Among transplant patients, those who developed GVHD showed longer OS 
      than those without GVHD (P < 0.05). URD donors and CMV-negative status donors 
      were associated with improved OS in transplant patients (P < 0.05). Importantly, 
      we observed a decreased Th/Tc ratio in BM at initial diagnostic in patients with 
      GVHD compared to those without GVHD (P = 0.034). Receiver operating 
      characteristic analysis indicated that a low Th/Tc ratio predicted an increased 
      risk of GVHD with a sensitivity of 44.44% and specificity of 87.50%. Moreover, an 
      increased T/NK ratio in BM of post-induction chemotherapy was found to be 
      associated with GVHD, with a sensitivity of 75.76% and specificity of 65.22%. 
      Additionally, we observed a decreased percentage of NK1 (CD56-CD16+NK) in PB on 
      day 100 post-transplantation in the GVHD group (P < 0.05). These three indicators 
      exhibit promising potential as specific and useful biomarkers for predicting 
      GVHD. These findings provide valuable insights for the early identification and 
      management of GVHD risk, thereby facilitating the possibility of improving 
      patient outcomes.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of the 
      British Society for Immunology. All rights reserved. For permissions, please 
      e-mail: journals.permissions@oup.com.
FAU - Wang, Weiwei
AU  - Wang W
AUID- ORCID: 0000-0001-6849-1406
AD  - Department of Clinical Laboratory, Xinhua Hospital, Shanghai Jiaotong University 
      of Medicine School, Shanghai, 200092, China.
FAU - Li, Haibo
AU  - Li H
AD  - Department of Pathology and Laboratory Medicine, Oregon Health and Science 
      University, Portland, OR, 97239, USA.
AD  - Hematology/Flow Cytometry lab, Department of Pathology, University of California 
      Irvine Medical Center, Orange, CA, 92868, USA.
FAU - Guo, Yukun
AU  - Guo Y
AD  - Casey Eye Institution, Oregon Health and Science University, Portland, OR, 97239, 
      USA.
FAU - Zhang, Lihua
AU  - Zhang L
AD  - Department of Clinical Laboratory, Xinhua Hospital, Shanghai Jiaotong University 
      of Medicine School, Shanghai, 200092, China.
FAU - Jiang, Wenli
AU  - Jiang W
AD  - Department of Clinical Laboratory, Xinhua Hospital, Shanghai Jiaotong University 
      of Medicine School, Shanghai, 200092, China.
FAU - Zheng, Naisheng
AU  - Zheng N
AD  - Department of Clinical Laboratory, Xinhua Hospital, Shanghai Jiaotong University 
      of Medicine School, Shanghai, 200092, China.
FAU - Peng, Se
AU  - Peng S
AD  - Department of Laboratory Medicine, Guangdong Provincial Hospital of Chinese 
      Medicine, Zhuhai, 519015, China.
FAU - Guan, Xiaolin
AU  - Guan X
AD  - Department of Clinical Laboratory, Xinhua Hospital, Shanghai Jiaotong University 
      of Medicine School, Shanghai, 200092, China.
FAU - Fan, Guang
AU  - Fan G
AD  - Department of Pathology and Laboratory Medicine, Oregon Health and Science 
      University, Portland, OR, 97239, USA.
FAU - Shen, Lisong
AU  - Shen L
AD  - Department of Clinical Laboratory, Xinhua Hospital, Shanghai Jiaotong University 
      of Medicine School, Shanghai, 200092, China.
AD  - Faculty of Medical Laboratory Science, College of Health Science and Technology, 
      Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
AD  - Institute of Artificial Intelligence Medicine, Shanghai Academy of Experimental 
      Medicine, Shanghai, 200070, China.
LA  - eng
GR  - HYWJ201605/Shanghai Medicine and Health Development Foundation/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
SB  - IM
MH  - Humans
MH  - Bone Marrow Transplantation/adverse effects/methods
MH  - *Leukemia, Myeloid, Acute
MH  - *Graft vs Host Disease
MH  - *Hematopoietic Stem Cell Transplantation/methods
MH  - Transplantation, Homologous
MH  - Retrospective Studies
PMC - PMC10847816
OTO - NOTNLM
OT  - BM microenvironment
OT  - BM transplant
OT  - acute myeloid leukemia (AML)
OT  - graft-versus-host-disease (GVHD)
OT  - immune dynamic
COIS- The authors declare no conflicts of interest.
EDAT- 2023/11/17 15:26
MHDA- 2024/02/08 06:42
PMCR- 2024/11/16
CRDT- 2023/11/16 09:53
PHST- 2023/03/23 00:00 [received]
PHST- 2023/09/16 00:00 [revised]
PHST- 2023/11/15 00:00 [accepted]
PHST- 2024/11/16 00:00 [pmc-release]
PHST- 2024/02/08 06:42 [medline]
PHST- 2023/11/17 15:26 [pubmed]
PHST- 2023/11/16 09:53 [entrez]
AID - 7424503 [pii]
AID - uxad123 [pii]
AID - 10.1093/cei/uxad123 [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2024 Feb 7;215(2):148-159. doi: 10.1093/cei/uxad123.